All Stories

UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake.

Feb 14, 2025 - 15:29
 0
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake.
Read More

Tags:

Previous Article

Infineon: Project “GENIAL!”: Joint electronics roadmap for innovations in the au...

Next Article

Symmetry’s Domain

Related Posts

Novartis pumps $7.5M into push to save 100,000 lives from prostate cancer by 2035

Novartis pumps $7.5M into push to save 100,000 lives fr...

Feb 19, 2025  0

After high-profile pledge to secure confirmation, RFK Jr. now says panel will review childhood vaccine schedules

After high-profile pledge to secure confirmation, RFK J...

Feb 19, 2025  0

Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod

Fierce Pharma Asia—Novo Nordisk's fraud accusation; Ast...

Feb 21, 2025  0